Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07106892 by Shanghai Henlius Biotech, with 60 participants planned, started 2025-09-15 and due to reach its primary completion in 2026-12-30. Interventions recorded: HLX43 Dose 1;, HLX43 Dose 2; and HLX43 Dose 3;.